Avoid common mistakes on your manuscript.
Correction to: Journal of Neurology https://doi.org/10.1007/s00415-023-11560-1
The original version of this article unfortunately contained a mistake. The corrected details are given below for your reading.
In figure 1, there is an error in the n numbers below the graph in Panel 1b for the placebo group. The n numbers underneath Panel 1b should be 58 58 50.
There is an error within Fig. 4. The dashed lines at ~ − 1.4 should be at 0. They have been moved downwards and are no longer in the correct place.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Oskoui, M., Day, J.W., Deconinck, N. et al. Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA). J Neurol 270, 2547–2549 (2023). https://doi.org/10.1007/s00415-023-11658-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-023-11658-6